GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market

GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why

GSK plc announced positive interim results from the DREAMM-7 trial for belantamab mafodotin in combination with BorDex for multiple myeloma. The study showed improved overall survival compared to standard treatment. Plans for further studies and filings in multiple countries are underway.